Breathe Well Live Well
Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?
J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):791-3
Authors: Liccardi G, Salzillo A, Calzetta L, Ora J, Cazzola M, Matera MG, Rogliani P
PMID: 27393788 [PubMed – in process]
View full post on pubmed: asthma
Conditions: COPD; LUNG DISEASES, OBSTRUCTIVE
Interventions: Device: Handihaler-Tiotropium 18 mcg untrained; Device: Handihaler-Tiotropium 18 mcg trained; Device: Respimat-Tiotropium 5 mcg trained
Sponsors: Imperial College London; Boehringer Ingelheim
Not yet recruiting – verified October 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: CHF 5993 200/6/12.5 µg; Drug: CHF 1535 200/6 µg; Drug: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
Sponsor: Chiesi Farmaceutici S.p.A.
Not yet recruiting – verified February 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
JAMA: The Journal of the American Medical Association |
LABAs, tiotropium perform similarly in black patients with asthma
Clinical Advisor HealthDay News — For black patients with asthma treated with inhaled corticosteroids (ICS), outcomes are similar with addition of tiotropium and long-acting ?-agonists (LABAs), according to a study published in the Journal of the American Medical … Anticholinergic vs Long-Acting ?-Agonist in Combination With Inhaled … LABAs No Better Than Tiotropium in Black Adults With Asthma |
View full post on asthma – Google News
European Pharmaceutical Review |
Spiriva Respimat (Tiotropium) Gets Asthma Indication in US
Medscape The US Food and Drug Administration (FDA) has approved the long-acting muscarinic antagonist tiotropium bromide (Spiriva Respimat, Boehringer Ingelheim) for long-term maintenance treatment of asthma in people aged 12 years and older, according to a … FDA approves Boehringer's asthma treatment FDA approves asthma treatment Spiriva Respimat |
View full post on asthma – Google News
Lung Disease News |
Tiotropium Therapy Shown As Safe and Effective Treatment for Adolescents with …
Lung Disease News Asthma is a common chronic inflammatory lung disease characterized by airflow obstruction that causes wheezing, shortness of breath, chest tightness and coughing. The respiratory disorder is estimated to affect 27 million individuals in the United States. |
View full post on asthma – Google News
|
Tiotropium safe, effective for asthma in adolescents
Healio “This systematic review of tiotropium for adolescents with symptomatic moderate to severe asthma suggests that tiotropium administered via an inhaler is well tolerated and efficacious as an addition to maintenance treatment with [inhaled … |
View full post on asthma – Google News
|
Tiotropium improved asthma control as add-on therapy to ICS
Healio “Our findings show that in patients with moderate asthma who are receiving medium-dose inhaled corticosteroids, addition of once-daily tiotropium significantly improves lung function and asthma control compared with placebo, and has similar efficacy … |
View full post on asthma – Google News
|
Boehringer Presents New Phase III Data for Asthma Therapy Tiotropium
Lung Disease News Boehringer Ingelheim Pharmaceutical company Boehringer Ingelheim recently presented encouraging data regarding its investigational drug tiotropium delivered through the company's Respimat inhaler, for the treatment of asthma. The data was presented … Tiotropium improves lung function in asthma, regardless of allergic status |
View full post on asthma – Google News
|
New Phase III Data in Asthma Patients Show Tiotropium Improves Lung Function …
PR Newswire (press release) HOUSTON, Feb. 21, 2015 /PRNewswire/ — Boehringer Ingelheim today presented data on investigational tiotropium delivered via Respimat® inhaler from five Phase III trials from the UniTinA-asthma® program at the 2015 American Academy of Allergy, … |
View full post on asthma – Google News